Rôles of Surface Factor and a Plasma Inhibitory Activity (Anti-SF) During Experimental Thrombosis in Rabbits^[*]

Summary

Intravenous injection of active surface factor (SF) preparations, in rabbits, induces a thrombotic tendency, which correlates with a hypercoagulability of the blood revealed with the thrombelastograph. These effects are largely dissipated within 10 minutes post-injection. Portal vein injections, or confirmed occlusion of the liver circulation, fail to show that the SF inactivation has any direct connection with the liver. Rabbit plasma normally contains a high titer of inhibitor (anti-SF), which shows no significant increase after the SF injections. The inhibition is chiefly “progressive” in rabbit plasma. Plasma anti-SF could largely explain the nonpersistence of hypercoagulability and thrombo-genic activity in the 10 min post-injection tests. These mechanisms may be an important element in the body defenses against any thrombotic tendency associated with increased SF activity.

^* Aided by USPHS Research Grant HE-01510-11 and NIH-(UNC) Institutional Research Grant HE-06350-03 for Thrombosis Research.

^** Present Address: Department of Medicine, Athena Clinic, Victoros Hugo 12, Athinai, Greece.

• References

• 1 Iatridis S. G, Ferguson J. H, Iatridis P. G. Thrombogenic properties of surface factor: Evidence for an anti-surface factor activity in canine plasma. Thrombos. Diathes. haemorrh. (Stuttg.) 12: 35 1964;
• 2 Wessler S, Reiner L, Freiman D. G, Reimer S. M, Lertzman M. Serum-induced thrombosis. Studies of its induction and evolution under controlled conditions in vivo. Circulation 20: 864 1959;
• 3 Waaler B. A. Contact activation in the intrinsic blood clotting system. Studies on a plasma product formed on contact with glass and similar surfaces. Scand. J. clin. Lab. Invest. 11 (Suppl. 37) 01 1959;
• 4 Ratnoff O.D, Davie E. W, Mallett D. L. Studies on the action of Hageman factor: Evidence that activated Hageman factor in turn activates plasma thromboplastin antecedent. J. clin. Invest. 40: 803 1961;
• 5 Henderson E. S, Rapaport S. I. The thrombotic activity of activation product. J. clin. Invest. 41: 235 1962;
• 6 Iatridis S. G, Ferguson J. H. A two-stage assay method for Hageman factor activity. Thrombos. Diathes. haemorrh. (Stuttg.) 8: 46 1962;
• 7 Wessler S, Reimer S. M, Sheps M. C. Biologic assay of a thrombosis-inducing activity in human serum. J. appl. Physiol. 44: 943 1959;
• 8 DeN icola P, Mazzetti G. M. Evaluation of thrombelastography. Amer. J. clin. Path. 25: 447 1955;
• 9 Ratnoff O. D, Rosenblum J. M. Role of Hageman factor in the initiation of clotting by glass: Evidence that glass frees Hageman factor from inhibition. Amer. J. Med. 25: 160 1958;
• 10 Margolis J. Initiation of blood coagulation by glass and related surfaces. J. Physiol. (Lond.) 137: 95 1957;